Ipamorelin vs. Sermorelin: What the Evidence Actually Shows

Ipamorelin and sermorelin get marketed as interchangeable "GH peptides" often enough that the actual comparison — which one has more evidence behind it, and which one you can even get through a legitimate provider — rarely gets a straight answer. Here's one, checked directly against the primary sources rather than a supplement page's summary of them.

They don't share a receptor, and that's not a technicality

Sermorelin is a GHRH-receptor agonist — a 29-amino-acid fragment of growth-hormone-releasing hormone, the signal the hypothalamus itself uses. Ipamorelin is a ghrelin-receptor agonist — a small pentapeptide that activates an entirely different receptor on the pituitary (GHS-R1a), the same one ghrelin binds. Both ultimately raise growth hormone, but through separate pathways. Our fuller three-way comparison of sermorelin, ipamorelin, and CJC-1295 covers that mechanism split in depth, including ipamorelin's own discovery paper, which describes it as the first ghrelin-receptor compound shown to be selective — in pigs, doses more than 200-fold above the GH-releasing threshold didn't raise cortisol or ACTH the way older compounds in the same class did¹. That selectivity claim is real. It's also a finding from anesthetized rats and conscious pigs, not a controlled human outcome trial — which is where the real gap between these two compounds opens up.

The evidence gap is not close

Sermorelin's evidence base is old, but it's real, controlled, and it exists at meaningful scale. The compound's own approval-era clinical literature is a review of its use "in the diagnosis and treatment of children with idiopathic growth hormone deficiency"² — a population studied across enough trials to win it FDA approval under the brand Geref in 1990, plus orphan-drug status in 1997⁵. The adult evidence is thinner — a 2017 retrospective chart review of just 14 qualifying men, on a combination of sermorelin and two other secretagogues, not sermorelin alone³ — but sermorelin at least has a real approval history to point to, even if that history is pediatric and the product is now discontinued (not for safety reasons — FDA's own record states the withdrawal was commercial⁵).

Ipamorelin's human evidence is thinner still, and it has never had an approval history of any kind. What exists: a 1999 dose-escalation pharmacokinetic study in eight healthy male volunteers per dose level, confirming intravenous ipamorelin triggers a single, time-limited GH pulse peaking around 40 minutes post-infusion with a roughly 2-hour half-life⁴ — a real mechanism confirmation, and a narrow one. The only randomized, placebo-controlled trial of ipamorelin that tested an actual clinical outcome is a 2014 multicenter Phase 2 trial for postoperative ileus — sluggish bowel function after abdominal surgery, based on ghrelin receptors' separate role in gut motility, tested in 114 hospitalized surgical patients. The primary endpoint, time to tolerating a solid meal, ran 25.3 hours with ipamorelin versus 32.6 hours with placebo — a difference that did not reach statistical significance (p = 0.15)⁶. That is the entire published record of a controlled ipamorelin outcome trial, and it missed. FDA's own compounding reviewers reached the same conclusion when they evaluated ipamorelin directly: citing that same 2014 trial, FDA's briefing document states there are "no data to support the effectiveness of ipamorelin... for the proposed [subcutaneous] route of administration" for either growth-hormone deficiency or postoperative ileus⁷. Nothing resembling a controlled trial of ipamorelin for body composition, fat loss, sleep, or anti-aging in adults exists in the published literature.

Neither is FDA-approved for what telehealth sells — but only one was ever approved for anything

Sermorelin's only FDA-approved product, Geref, is discontinued today, but it was a real, reviewed, approved drug for a real indication — pediatric growth-hormone deficiency — for years. Ipamorelin has never had an FDA-approved product of any kind, for any indication, at any point. A direct DailyMed search — the National Library of Medicine's official archive of FDA-approved drug labeling — returns zero results for ipamorelin, re-confirmed live for this article⁸. FDA's Pharmacy Compounding Advisory Committee reviewed ipamorelin at its October 29, 2024 meeting and recommended, item by item, against adding either ipamorelin free base or ipamorelin acetate to the Section 503A compounding bulk-substances list⁷. It doesn't currently appear in any of FDA's three nomination categories at all — not under active review, not flagged for safety concerns, simply never approved and not on the agency's current compounding watch-list.

The post-marketing signal — small for both, and different in kind

FDA's Adverse Event Reporting System (FAERS) holds 58 reports naming sermorelin, most commonly local and hypersensitivity-type reactions⁹, and 11 reports naming ipamorelin, counted live for this article — the single most frequent reaction coded against it is "recalled product administered" (4 of the 11)¹⁰. Both numbers are far too small to compute an incidence rate from — this is spontaneous reporting, not a trial — but the pattern is worth naming honestly rather than glossing over: ipamorelin's small FAERS signal is dominated by a sourcing problem (a recalled product reaching a patient), not a pharmacological adverse event, which says more about the supply chain selling it than about the molecule's own safety profile one way or the other.

What this means if you're actually choosing between them

If the decision is "which compound has more evidence behind it," sermorelin wins that comparison clearly — a real approval history (even if historical and pediatric) against zero approval history of any kind, and decades of trial literature against one missed-endpoint trial. If the decision is "which one can I get through a provider this site has actually reviewed," the answer is narrower still: our sermorelin provider rankings are this site's only board covering a growth-hormone secretagogue, and no provider on that roster sells ipamorelin as a boarded product. That's not a knock on ipamorelin specifically — this site's board doesn't cover CJC-1295, tesamorelin, or MK-677 either, for the same reason: none of them are what the reviewed roster actually sells.

Both compounds are prohibited in tested competitive sport, without exception — WADA's 2026 Prohibited List names sermorelin explicitly under GHRH analogs and ipamorelin explicitly under growth hormone secretagogues, both under category S2, prohibited at all times¹. Our full three-way comparison covers that citation directly if you want the primary document. If tesamorelin is the third option you're weighing instead, our sermorelin-vs-tesamorelin comparison and our MK-677 vs. sermorelin comparison cover the other two spokes of this same GH-axis cluster. Once you have an actual prescribed sermorelin dose, our reconstitution calculator converts it into a syringe volume; our ipamorelin calculator does the same arithmetic for ipamorelin, with no FDA-set vial strength to check it against.

The bottom line

Sermorelin and ipamorelin work through different receptors, and only one of them has ever had an FDA-approved product — sermorelin's, discontinued but real, for pediatric growth-hormone deficiency. Ipamorelin's evidence base is a single pharmacokinetic study and one placebo-controlled outcome trial that missed its endpoint, for an indication (bowel recovery after surgery) that has nothing to do with why it's marketed today. Neither is sold by a provider on this site's roster, and this site's only growth-hormone board covers sermorelin specifically — which is the honest reason this comparison keeps circling back to it.